| Revenue Growth | Total revenue up 158% to $57.9M; Hemangiol relaunch was primary driver. |
|---|---|
| Mgmt Confidence | Extremely high; claiming to be years ahead of aspirational long-term goals. |
| Demand Visibility | Record high active patient counts across all key branded products. |
| Margin Trends | Adjusted gross margin 80%; adjusted EBITDA margin expanded to 49%. |
| Op. Leverage | Significant; 50% EBITDA margin achieved despite $3M licensing expense. |
| Pricing Power | Hemangiol net price $8,000-$10,000; ASN-001 expected to have favorable Medicaid rebates. |
| Vol vs Price | Growth driven by both volume (patient counts) and favorable product mix. |
| Segment Growth | Strong performance across Ingrilux, Alkindi, Candidi, Desmoda, Galzin, and Carglumic assets. |
| New Clients | Licensed Libervant from Aquestive; licensed ET-900 patents from Baylor College. |
| Capex & Debt | $55.6M cash; $5M debt prepayment reduced principal balance to $22M. |
| Regulatory | Libervant PDUFA late March 2027; Candidi target action date May 2027. |
| Commentary | Management emphasizes building a leading rare disease company through aggressive late-stage licensing. |
| New Launches | Libervant launch April 2027; ASN-001 launch 2028; Anglidia launch 2027. |
Growth
Revenue grew 158% year-over-year to $57.9 million; adjusted EBITDA margin reached 49%.
Outlook
Raised 2026 revenue guidance to >$175M; targeting $500M revenue well ahead of 2030.
Risks
ET-700 proof-of-concept study showed slower-than-ideal release, requiring additional clinical arms in 2027.
The company's earnings call, NASDAQ: ETON, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Eton Pharmaceuticals, Inc.: key numbers
- Share price
- $63.88Close, Nov 16
- Market cap
- $1.84B
- Shares outstanding
- 28.84MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Eton Pharmaceuticals, Inc.
All →Eton Pharmaceuticals Chief Commercial Officer Ipek Erdogan-Trinkaus Sells $236K of Stock
Ipek Erdogan-Trinkaus, Chief Commercial Officer, sold 3,500 shares of Eton Pharmaceuticals, Inc. at $67.18 to $67.88 a share (average $67.41) in 2 transactions, worth $236K in total on Nov 10, 2026. Shares held after the trade: 4,081 (-22.1%).
- Value
- $236K
- Shares
- 3,500
- Average price
- $67.41
- Role
- Chief Commercial Officer
- Holding change
- -22.1%
- Trade date
- Nov 10, 2026
Eton Pharmaceuticals Insider Charles J. Casamento Sells $5.35M of Stock
Charles J. Casamento sold 80,555 shares of Eton Pharmaceuticals, Inc. at $64.33 to $67.87 a share (average $66.35) in 5 transactions, worth $5.35M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $5.35M
- Shares
- 80,555
- Average price
- $66.35
- Holding change
- -100.0%
- Trade date
- Nov 10, 2026
Eton Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $35.2M
Eton Pharmaceuticals reported a significant increase in net revenues to $57.9 million for the third quarter of 2026, driven by strong product sales. The company achieved a net income of $35.2 million for the quarter, aided by a $12.9 million income tax benefit related to the reversal of a deferred tax asset valuation allowance.
- Key figure
- Net income $35.2M
Eton Pharmaceuticals Financial Results
Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.
- Term
- Q3 2026
“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Eton Pharmaceuticals Clinical Trial Data
Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
- Counterparty
- Baylor College of Medicine